The potential of incretin-based therapies in type 1 diabetes

Drug Discovery Today

Volumn 17, Issue 1-2, 2012, Pages 89-95

  Suen, Chen S ^a   Burn, Paul ^a  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INCRETIN; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN;

APPETITE; CELL REGENERATION; DIABETES MELLITUS; DISEASE COURSE; DRUG ACTIVITY; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN SECRETION; REVIEW; STOMACH EMPTYING;

ANIMALS; DIABETES MELLITUS, TYPE 1; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; INSULIN-SECRETING CELLS;

EID: 84855843988     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.08.017     Document Type: Review

References (75)

1. S. Perl Significant human beta-cell turnover is limited to the first three decades of life as determined by in vivo thymidine analog incorporation and radiocarbon dating J. Clin. Endocrinol. Metab. 95 2010 234 239
2. H.A. Keenan Residual insulin production and pancreatic β cell turnover after 50 years of diabetes: Joslin Medalist Study Diabetes 59 2010 2846 2853
3. S. Bonner-Weir Beta-cell growth and regeneration: replication is only part of the story Diabetes 59 2010 2340 2348
4. P. Burn Type 1 diabetes Nat. Rev. Drug Discov. 9 2010 187 188
5. M.J. Perley, and D.M. Kipnis Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects J. Clin. Invest. 46 1967 1954 1962
6. H. Elrick Plasma insulin response to oral and intravenous glucose administration J. Clin. Endocrinol. Metab. 24 1964 1076 1082
7. D.C. Klonoff Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years Curr. Med. Res. Opin. 24 2008 275 286 (Pubitemid 351160260)
8. N.M. Yoon Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting Clin. Ther. 31 2009 1511 1523
9. V. Preumont Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity Diabetes Metab. 36 2010 293 298
10. A. Garber Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial The Lancet 373 2009 473 481
11. J.B. Buse Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) The Lancet 374 2009 39 47
12. S. Dhillon Sitagliptin: a review of its use in the management of type 2 diabetes mellitus Drugs 70 2010 489 512
13. R.E. Pratley Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial The Lancet 375 2010 1447 1456
14. J. Pinkney Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide Ther. Clin. Risk Manag. 6 2010 401 611
15. M. Elashoff Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies Gastroenterology 141 2011 150 156
16. S.S. Engel Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis Int. J. Clin. Pract. 64 2010 984 990
17. S. Mudaliar, and R.R. Henry Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function Am. J. Med. 123 2010 19 27
18. F.C. Schuit, and D.J. Drucker Beta-cell replication by loosening the brakes of glucagon-like peptide-1 receptor signaling Diabetes 57 2008 529 531
19. T. Xie Pancreas-specific Gsα deficiency has divergent effects on pancreatic alpha- and beta-cell proliferation J. Endocrinol. 206 2010 261 269
20. Z. Liu, and J.F. Habener Wnt signaling in pancreatic islets Adv. Exp. Med. Biol. 654 2010 391 419
21. A. Maida Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 receptor signaling for beta cell survival in mice Gastroenterology 137 2009 2146 2157
22. M. Cornu Glucagon-like peptide-1 increases beta-cell glucose competence and proliferation by translational induction of insulin-like growth factor-1 receptor expression J. Biol. Chem. 285 2010 10538 10545
23. J. Quoyer GLP-1 mediates anti-apoptotic effect by phosphorylating Bad through a beta-arrestin 1-mediated ERK1/2 activation in pancreatic beta-cells J. Biol. Chem. 285 2010 1989 2002
24. M. Karaca Functional pancreatic beta-cell mass: involvement in type 2 diabetes and therapeutic intervention Diabetes Metab. 35 2009 77 84
25. S. Tsunekawa Protection of pancreatic beta-cells by exendin-4 may involve the reduction of endoplasmic reticulum stress; in vivo and in vitro studies J. Endocrinol. 193 2007 65 74 (Pubitemid 46638533)
26. A. Natalicchio Exendin-4 prevents c-Jun N-terminal protein kinase activation by tumor necrosis factor-alpha (TNFalpha) and inhibits TNFalpha-induced apoptosis in insulin-secreting cells Endocrinology 151 2010 2019 2029
27. D.Y. Kwon Exendin-4 potentiates insulinotropic action partly via increasing beta-cell proliferation and neogenesis and decreasing apoptosis in association with the attenuation of endoplasmic reticulum stress in islets of diabetic rats J. Pharmacol. Sci. 111 2009 361 371
28. B. Rolin The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice Am. J. Physiol. Endocrinol. Metab. 283 2002 E745 E752
29. S. Bregenholt The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro Biochem. Biophys. Res. Commun. 330 2005 577 584 (Pubitemid 40417684)
30. S. Merani Liraglutide, a long-acting human glucagon-like peptide-1 analog, improves glucose homeostasis in marginal mass islet transplantation in mice Endocrinology 149 2008 4322 4328
31. M.C. Bunck One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial Diabetes Care 32 2009 762 768
32. S. Madsbad Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) - preclinical and clinical results Best Pract. Res. Clin. Endocrinol. Metab. 23 2009 463 477
33. J. Mu Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes Diabetes 55 2006 1695 1704 (Pubitemid 44324122)
34. D.M. Riche Impact of sitagliptin on markers of beta-cell function: a meta-analysis Am. J. Med. Sci. 337 2009 321 328
35. R. Henry β-Cell stimulation by Saxagliptin in patients with type 2 diabetes Diabetes 58 Suppl. 1 2009 447
36. I. Hadjiyanni Exendin-4 modulates diabetes onset in nonobese diabetic mice Endocrinology 149 2008 1338 1349 (Pubitemid 351397945)
37. N.A. Sherry Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells Endocrinology 148 2007 5136 5144 (Pubitemid 350012634)
38. W.L. Suarez-Pinzon Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice Diabetes 57 2008 3281 3288
39. B. Tian Upregulating CD4+CD25+FOXP3+ regulatory T cells in pancreatic lymph nodes in diabetic NOD mice by adjuvant immunotherapy Transplantation 87 2009 198 206
40. C.A. Sheffield Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection Pharmacotherapy 27 2007 1449 1455 (Pubitemid 47530451)
41. A.N. Paisley Stabilizing effect of exenatide in a patient with C-peptide-negative diabetes mellitus Diabet Med 26 2009 935 938
42. W.O. Creutzfeldt Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I (7-36) amide in type 1 diabetic patients Diabetes Care 19 1996 580 586
43. J. Dupré Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes J. Clin. Endocrinol. Metab. 89 2004 3469 3473 (Pubitemid 38951922)
44. K.I. Rother Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes Diabetes Care 32 2009 2251 2257
45. K.A. Ghofaili Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes Transplantation 83 2007 24 28 (Pubitemid 46104966)
46. R.N. Faradji Long-term metabolic and hormonal effects of exenatide on islet transplant recipients with allograft dysfunction Cell Transplant. 18 2009 1247 1259
47. T. Froud The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects Transplantation 86 2008 36 45
48. U. Kielgast Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function Diabetes 60 2011 1599 1607
49. U. Kielgast Four weeks of treatment with Liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual {beta}-cell function Diabetes Care 34 2011 1463 1468
50. A. Varanasi Liraglutide as additional treatment for type 1 diabetes Eur. J. Endocrinol. 165 2011 77 84
51. K. Ohnuma Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function Trends Immunol. 29 2008 295 301
52. D. Reinhold Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice Clin. Chem. Lab. Med. 47 2009 268 274
53. K. Ohnuma Soluble CD26/dipeptidyl peptidase IV induces T cell proliferation through CD86 up-regulation on APCs J. Immunol. 167 2001 6745 6755 (Pubitemid 33144164)
54. S.L. Conarello Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance Proc. Natl. Acad. Sci. U.S.A. 100 2003 6825 6830 (Pubitemid 36666664)
55. S. Yan Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen Eur. J. Immunol. 33 2003 1519 1527 (Pubitemid 36790412)
56. R. Yazbeck Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol. Sci. 30 2009 600 607
57. +) memory T cells with high CD26 surface expression are enriched for Th1 markers and correlate with clinical severity of multiple sclerosis J. Neuroimmunol. 181 2006 157 164 (Pubitemid 44834421)
58. A. Schmiedl Reduced airway inflammation in CD26/DPP4-deficient F344 rats is associated with altered recruitment patterns of regulatory T cells and expression of pulmonary surfactant proteins Clin. Exp. Allergy 40 2010 1794 1808
59. C. Sia, and A. Hänninen Functional alterations of proinflammatory monocytes by T regulatory cells: implications for the prevention and reversal of type 1 diabetes Rev. Diabet. Stud. 7 2010 6 14
60. J.A. Pospisilik Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats Diabetes 52 2003 741 750 (Pubitemid 36323582)
61. J.A. Pospisilik Dipeptidyl peptidase IV inhibition in animal models of diabetes Adv. Exp. Med. Biol. 524 2003 281 291 (Pubitemid 36570837)
62. W.L. Suarez-Pinzon Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice Diabetologia 52 2009 1680 1682
63. L. Tian Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor Endocrinology 151 2010 3049 3060
64. S.J. Kim Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice Diabetes 57 2008 1331 1339
65. S.J. Kim Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways Diabetes 59 2010 1739 1750
66. C.E. Couri C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus JAMA 301 2009 1573 1579
67. E. Kutoh Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series J. Med. Case Rep. 5 2011 117 121
68. J.E. Foley Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes Horm. Metab. Res. 40 2008 727 730
69. K.C. Herold Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years Clin. Immunol. 132 2009 166 173
70. B. Keymeulen Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass Diabetologia 53 2010 614 623
71. M.D. Pescovitz Rituximab, B-lymphocyte depletion, and preservation of beta-cell function N. Engl. J. Med 361 2009 2143 2152
72. J. Ludvigsson GAD treatment and insulin secretion in recent-onset type 1diabetes N. Engl. J. Med. 359 2008 1909 1920
73. N. Sherry Teplizumab for treatment of type 1 diabetes(Proté gé study): 1-year results from a randomized, placebo-controlled trial The Lancet 378 2011 487 497
74. D.K. Wherrett Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomized double-blind trial The Lancet 378 2011 319 327
75. C. Greenbaum, and M.A. Atkinson Persistence is the twin sister of excellence. An important lesson for attempts to prevent and reverse type 1 diabetes Diabetes 60 2011 693 694